GnRH agonist peptide
Triptorelin
Triptorelin's elimination half-life was 2.8 hours in healthy men after a 0.5 mg intravenous dose, and the app lists 3 hours for the single subcutaneous dose.1
Triptorelin after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.
Drawn from the half-life in the app's model, ~3 h. The model's figures
- Compound
- Triptorelin
- Symbol
- TRP
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist, sold in the United States as Trelstar and Triptodur.2,3 The Trelstar label lists one use, advanced prostate cancer, and the Triptodur label lists pediatric patients 2 years and older with central precocious puberty.2,3 Both labels give 2000 as the initial US approval year.2,3
The app files triptorelin under post-cycle therapy as a GnRH agonist taken by subcutaneous injection, with typical doses of 100 to 200 mcg. The app's notes separate a single immediate-release dose, described as a one-shot restart of the hypothalamic-pituitary-testicular axis, from the long-acting depot form, which suppresses the axis. The app grades the evidence as strong. No controlled trial in people of a single subcutaneous triptorelin dose as a restart of the hypothalamic-pituitary-testicular axis after anabolic steroid use was identified in PubMed or ClinicalTrials.gov. The human evidence cited below comes from pharmacokinetic work, diagnostic stimulation tests, ovulation-trigger dose studies, and the depot labels.
How it works
Sources in this part
The Trelstar label describes triptorelin as a "synthetic decapeptide agonist analog of gonadotropin releasing hormone (GnRH)".2 The same label reports, from in vitro work on rat pituitary cells, that triptorelin "was 100-fold more active than native GnRH in stimulating luteinizing hormone release".2
Following the first administration, the Trelstar label reports "a transient surge in circulating levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, and estradiol".2 After chronic and continuous administration, "usually 2 to 4 weeks after initiation of therapy, a sustained decrease in LH and FSH secretion and marked reduction of testicular steroidogenesis are observed", and the label adds that "These effects are usually reversible after cessation of therapy".2 The Triptodur label gives the same sequence in children with central precocious puberty, with the sustained decrease in LH and FSH "by 4 weeks after initiation of therapy".3
Evans and colleagues reported the same switch with daily dosing of an LHRH agonist analog in 13 normal men, in the Journal of Clinical Endocrinology and Metabolism in 1984.4 On the first day of treatment, tested in four of the men, "there were significant increases in LH, FSH, and testosterone".4 After 4 weeks, "all men had dramatic decreases in mean testosterone levels and blunted or absent gonadotropin responses to acute injection of LHRHA".4 The analog in that study is named D-Trp6,Pro9-NEt LHRH, so it is a class-level result and not a triptorelin result, and the Leydig cells still responded to exogenous human LH.4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~3 h
- Bioavailability
- 90%
- Typical dose
- 100–200 mcg
- Route
- SubQ
- Time to peak
- ~1 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~3 h (single subcutaneous dose) | Geometric mean elimination half-life of 2.8 h in six healthy men after a 0.5 mg intravenous bolus, and 6.6 h, 7.7 h and 7.6 h in the groups with renal or hepatic insufficiency; the Trelstar label gives distribution and elimination half-lives of approximately 6 minutes, 45 minutes and 3 hours in healthy men after an intravenous bolus1,2 |
| Bioavailability | 90% | No subcutaneous bioavailability figure for triptorelin was identified in the labels and papers cited here2,1 |
| Time to peak | ~1 h | Mean peak serum triptorelin concentrations "occurred in 1 to 3 hours" after a single intramuscular Trelstar injection (3.75, 11.25 or 22.5 mg depot) in men with prostate cancer; in the Triptodur label, triptorelin "peaked 4 hours postdose" after a 22.5 mg intramuscular injection in children 2 to 9 years old with central precocious puberty2,3 |
| Duration of effect | 24 h | Ahn and colleagues, describing Freire and colleagues, report that after a 100 µg subcutaneous injection the peak LH level "was observed at 3 h post-injection, and serum LH levels remained above baseline after 24 h" (girls, diagnostic test)5 |
| Volume of distribution | Not given | 30 to 33 L after a single intravenous 0.5 mg dose in healthy male volunteers; "no evidence" of binding to plasma proteins at clinically relevant concentrations2 |
The 2.8 hours of Müller and colleagues describes a single intravenous dose in healthy men, with longer half-lives in the renal and hepatic insufficiency groups; the app's 3 hours is its figure for a single subcutaneous dose, with no population stated. Elimination is by liver and kidney: the Trelstar label states that "Triptorelin is eliminated by both the liver and the kidneys", and that subjects with renal or hepatic impairment "had 2- to 4-fold higher exposure (AUC values) than young healthy males".2
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Müller and colleagues, British Journal of Clinical Pharmacology 19971 | Open pharmacokinetic study; two authors at Debiopharm SA1 | Four groups of six men: healthy, two renal insufficiency groups, one hepatic insufficiency group1 | Single intravenous bolus of 0.5 mg triptorelin acetate1 | Geometric mean elimination half-life 2.8 h in healthy men against 6.6, 7.7 and 7.6 h in the impairment groups; total clearance 210, 113, 86.8 and 57.3 ml per minute1 |
| Ahn and colleagues, Children 20235 | Retrospective chart review; no company named, university research fund support5 | 220 girls: 111 with central precocious puberty and 109 with idiopathic premature thelarche5 | Triptorelin 0.1 mg subcutaneous, LH sampled to 120 or 180 min (146 girls); gonadorelin 100 µg intravenous in 74 girls5 | Peak LH of 4.52 IU/L or more at 120 min gave sensitivity 100% and specificity 95.83% for central precocious puberty5 |
| Ozkan and colleagues, Turkish Journal of Pediatrics 20016 | Retrospective evaluation of a modified test with clinical follow-up6 | 23 boys aged 14 to 16.5 years: 16 with constitutional delay of puberty, 7 with hypogonadotropic hypogonadism6 | Single triptorelin dose; follow-up of up to 24 months; dose not given in the PubMed record6 | LH at 4 h 33.2 +/- 9.3 against 3.3 +/- 2.6 mIU/ml, and testosterone at 24 h 369.3 +/- 128.1 against 61.4 +/- 22.6 ng/dl, constitutional delay against hypogonadotropic hypogonadism6 |
| Evans and colleagues, Journal of Clinical Endocrinology and Metabolism 19844 | Uncontrolled physiology study of a different LHRH agonist analog; NIH grants4 | 13 normal men4 | 50 micrograms per day for up to 8 weeks4 | Increases in LH, FSH and testosterone on day 1 (tested in 4 of the 13 men), then marked testosterone decreases in all men after 4 weeks and a lost pulsatile LH pattern; mean gonadotropin levels at 4 and 8 weeks were variable4 |
| Vuong and colleagues, Fertility and Sterility 20167 | Single-center, randomized, parallel, investigator-blinded trial7 | 165 oocyte donors aged 18 to 35 years7 | Triptorelin 0.2, 0.3 or 0.4 mg as ovulation trigger; route not given in the PubMed record7 | Metaphase II oocytes 16.0 ± 8.5, 15.9 ± 7.8 and 14.7 ± 8.4, no significant difference; LH at 24 and 36 hours higher with 0.4 mg; one patient with early-onset severe ovarian hyperstimulation syndrome7 |
| Lainas and colleagues, Human Reproduction 20198 | Retrospective study; no external funding8 | 131 infertile patients at high risk for severe ovarian hyperstimulation syndrome8 | Triptorelin 0.1 mg (n = 42), 0.2 mg (n = 46) or 0.4 mg (n = 43) as trigger8 | Median oocyte maturation rate 82.6%, 83.3% and 85.1% (P = 0.686); no significant differences in serum LH, FSH, estradiol or progesterone at any time point8 |
| Trelstar 3.75 mg trial, label, 20262 | Randomized, active control trial; manufacturer's label2 | 277 men with advanced prostate cancer, aged 47 to 89 years2 | Triptorelin 3.75 mg (n = 140) or another GnRH agonist monthly for 9 months, intramuscular2 | Castration-level testosterone at Day 29 in 125 of 137 (91.2%); maintained from Day 57 through Day 253 in 96.2%2 |
| Debiopharm 6-month formulation, NCT016561619 | Phase 3, single group, no masking; sponsor Debiopharm International SA9 | 120 men with advanced prostate cancer9 | Triptorelin embonate 22.5 mg subcutaneous on Day 1 and Day 1699 | Castrate testosterone by Day 29 in 98.33% and maintained from Day 57 to Day 337 in 82.61%; serious events in 17 of 120; 7 of 120 did not complete, including 3 deaths and 2 withdrawals for adverse events9 |
Deeper analysis: Müller and colleagues, pharmacokinetics in men
Müller and colleagues, working at the FARMOVS Research Centre, University of the Orange Free State, Bloemfontein, reported this study in the British Journal of Clinical Pharmacology in 1997.1 It gave a single intravenous bolus of 0.5 mg triptorelin acetate to four groups of six men, so it describes the peptide's disposition and says nothing of the subcutaneous route or of hormone responses.1 Serum concentrations "were adequately described by a three-compartment model", with distribution half-lives of "about 0.1 h (6 min) and 0.75 h (45 min)".1 Maximum concentrations were similar across groups, while "The total clearance of triptorelin decreased with increasing renal impairment, and was even lower in patients with hepatic insufficiency".1 The authors conclude that "the liver plays the predominant role in subjects suffering from some degree of renal impairment".1 The record lists no limitations and no adverse-event data, and gives no funding statement; two of the ten authors (Porchet and Weiner) are affiliated with Debiopharm SA, Lausanne, and the Trelstar label names Debiopharm Research & Manufacturing SA as manufacturer.1,2
Deeper analysis: Ahn and colleagues, subcutaneous triptorelin stimulation test
Ahn and colleagues reported the study in the journal Children in 2023, from Jeju National University Hospital and Soonchunhyang University Cheonan Hospital in Korea.5 It is a retrospective chart review of girls tested between 1 March 2020 and 28 February 2023, who had either the gonadorelin test or the triptorelin test according to which was available.5 A peak LH of "≥5.0 IU/L was considered to indicate HPG axis activation", and the measured outcome was the diagnostic accuracy of stimulated LH.5 In the triptorelin group, "most girls with CPP exhibited a peak LH response 60–180 min after subcutaneous triptorelin injection (n = 68)".5 In the 120-minute group, "59.5% and 27% exhibited peak LH values at 120 and 60 min, respectively".5 The authors give these limitations: "The girls had undergone only one of the two tests, and normal prepubertal girls were not included in this study", the design "was retrospective", and "the sample size of this study was relatively small, and all girls were Korean".5 Funding was the Soonchunhyang University Research Fund, and the authors declare no conflict of interest.5 The paper reports no adverse-event data for the tests, and the participants were girls with suspected precocious puberty, not men recovering from a steroid cycle.5
Deeper analysis: Vuong and colleagues and Lainas and colleagues, trigger doses
Vuong and colleagues (Fertility and Sterility, 2016) randomised 165 oocyte donors to 0.2, 0.3 or 0.4 mg triptorelin as the ovulation trigger in a GnRH antagonist cycle, with the primary end point the number of metaphase II oocytes.7 Their conclusion was that there were "No significant differences between triptorelin doses of 0.2, 0.3, and 0.4 mg used for ovulation trigger in oocyte donors" for mature oocytes and top-quality embryos.7 Secondary findings were higher LH at 24 and 36 hours and higher progesterone at oocyte pick-up plus 6 days with 0.4 mg, and one patient developed early-onset severe ovarian hyperstimulation syndrome.7 The PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and gives no limitations or author ties to a manufacturer; the registration number is NCT02208986.7 Lainas and colleagues (Human Reproduction, 2019) compared 0.1, 0.2 and 0.4 mg in 131 patients at high risk of severe ovarian hyperstimulation syndrome and reported similar maturation rates and similar LH and FSH levels at every time point.8 Their stated limitation is that "the presence of bias cannot be excluded", as the study was retrospective.8 They report no external funding and no conflicts of interest.8 The record does not give the rate of severe ovarian hyperstimulation syndrome by group.8 Both studies were in women having ovarian stimulation, and neither measured testosterone or involved men.7,8
Deeper analysis: the Trelstar label trials and NCT01656161
The Trelstar label describes three depot trials in men with advanced prostate cancer: 277 men on 3.75 mg or an approved GnRH agonist, 346 men on 11.25 mg every 12 weeks or 3.75 mg every 28 days, and a non-comparative trial of 120 men on 22.5 mg every 24 weeks.2 Castration-level testosterone was reached at Day 29 in 167 of 171 (97.7%) on 11.25 mg, with maintenance from Day 57 through Day 253 in 94.4%.2 For the 3.75 mg trial, 124 of 126 evaluable patients (98.4%) on Day 85 had LH of 1.0 IU/L or less at 2 hours after dosing, "indicating desensitization of the pituitary gonadotroph receptors".2 The label summarises these trials without naming a trial sponsor or listing limitations, and it names Debiopharm Research & Manufacturing SA as manufacturer.2 The registry entry NCT01656161 names Debiopharm International SA as lead sponsor and lists a single-group phase 3 design with no masking in 120 participants.9 It reports castrate testosterone achieved by Day 29 in 98.33% (95% CI 94.11 to 99.80) and maintained from Day 57 to Day 337 in 82.61% (95% CI 74.43 to 89.04).9 For its non-comparative trial of 120 men on 22.5 mg every 24 weeks, the Trelstar label reports castration at Day 29 in 97.5% (117 of 120) and maintained from Day 57 to Day 337 in 93.3%, against 98.33% and 82.61% in the registry entry; the label does not say how this trial relates to NCT01656161.2 Among the 120 participants, 17 had serious events and 117 had other events above the 5% reporting threshold, including hot flush in 86.9 Of the 120, 113 completed and 7 did not, including 3 deaths and 2 withdrawals for adverse events.9
Doses reported in studies and on labels
The app's 100 to 200 mcg range describes a single aqueous subcutaneous dose; the label doses below are multi-milligram depot injections and are a different formulation.
| Source | Dose and route | People and n | Schedule or length | Comparator and note |
|---|---|---|---|---|
| Müller 19971 | 0.5 mg intravenous bolus1 | 24 men in four groups of six1 | Single dose1 | Groups differ by renal or hepatic function; no placebo1 |
| Ahn 20235 | 0.1 mg subcutaneous5 | 146 girls (74 with a 180 min test, 72 with a 120 min test)5 | Single dose; LH and FSH sampled for 120 or 180 min5 | Gonadorelin 100 µg intravenous in 74 other girls5 |
| Earlier studies as described by Ahn 2023 (Poomthavorn, Freire, Vukovic)5 | 100 µg subcutaneous5 | Girls evaluated for central precocious puberty; n not given in the passage5 | Single dose; samples to 120 min, to 24 h, and to 180 min in the three studies5 | Described second-hand; Freire and colleagues compared triptorelin with gonadorelin, and Poomthavorn and colleagues lacked a normal control group5 |
| Vuong 20167 | 0.2, 0.3 or 0.4 mg; route not given in the PubMed record7 | 165 oocyte donors7 | Single trigger dose in an antagonist cycle7 | The three doses are each other's comparator; no hCG arm in the record7 |
| Lainas 20198 | 0.1, 0.2 or 0.4 mg; route not given in the PubMed record8 | 131 patients: 42, 46 and 438 | Single trigger dose; hormones sampled to 10 days8 | The three doses are each other's comparator; retrospective8 |
| Trelstar label2 | 3.75 mg, 11.25 mg or 22.5 mg intramuscular depot2 | Adults with advanced prostate cancer (trials of 277, 346 and 120 men)2 | Every 4 weeks, every 12 weeks, or every 24 weeks2 | The label states that the strengths are "not additive" and depend on the schedule2 |
| NCT016561619 | 22.5 mg subcutaneous (6-month formulation)9 | 120 men with advanced prostate cancer9 | Day 1 and Day 169, to Day 3379 | Single group, no comparator9 |
Side effects reported
The adverse-event data below come from depot products used for prostate cancer or precocious puberty, and not from the single aqueous dose. For Trelstar, the label lists the most common adverse reactions (5% or more) as hot flushes, skeletal pain, impotence and headache with the 3.75 mg strength, and hot flushes, erectile dysfunction and testicular atrophy with 22.5 mg.2 The Trelstar label warns that "Initially, triptorelin (TRELSTAR), like other GnRH agonists, causes a transient increase in serum testosterone levels", with possible worsening of prostate cancer symptoms in the first weeks (tumor flare).2 Its other warnings include metabolic changes such as hyperglycemia, diabetes mellitus and hyperlipidemia; convulsions; severe cutaneous adverse reactions; and possible QT/QTc prolongation with androgen deprivation therapy.2 On cardiovascular risk, the label states: "Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists (including TRELSTAR) in men", and adds that "The risk appears low based on the reported odds ratios".2 The Triptodur label reports psychiatric events with GnRH agonists, including "emotional lability, such as crying, irritability, impatience, anger, and aggression", and pseudotumor cerebri in pediatric patients.3 Both labels list a known hypersensitivity to triptorelin or other GnRH agonists as a contraindication.2,3 In the Debiopharm 6-month trial registry entry, hot flush was reported in 86 of 120 participants and serious events in 17 of 120, and 3 of the 7 participants who did not complete died.9 In the Vuong trial of ovulation-trigger doses, one patient developed early-onset severe ovarian hyperstimulation syndrome.7 Reports on the stimulation tests by Ahn and Ozkan, and on the Lainas trigger study, do not give adverse-event rates in the passages cited here.5,6,8
Bloodwork and markers
The app lists LH, FSH and total testosterone as markers to monitor. After a single intramuscular Trelstar 3.75 mg injection in healthy male volunteers, "serum testosterone levels first increased, peaking on Day 4, and declined thereafter to low levels by Week 4".2 The label tells prescribers to "Monitor serum levels of testosterone following injection of TRELSTAR", for patients with advanced prostate cancer.2 It also states that diagnostic tests of pituitary-gonadal function during treatment and after cessation of therapy "may therefore be misleading".2 In the stimulation-test papers, LH was the main read-out: in boys, LH at 4 h and testosterone at 24 h separated constitutional delay of puberty from hypogonadotropic hypogonadism, and in girls a peak LH of 5.0 IU/L or more indicated axis activation.6,5 In the Evans study, the pulsatile LH pattern was lost during daily analog treatment, and mean gonadotropin levels at 4 and 8 weeks were "variable".4 None of the sources cited here gives a testosterone, LH or FSH time course after a single subcutaneous triptorelin dose in men recovering from anabolic steroid use.
Regulatory and anti-doping status
The FDA-approved US labels cited here are Trelstar, for advanced prostate cancer, and Triptodur, for central precocious puberty in children 2 years and older.2,3 Neither label lists restarting the hypothalamic-pituitary-testicular axis as a use.2,3 The 2026 WADA Prohibited List names triptorelin in section S2.2.1, "Testosterone-stimulating peptides in males", as an example of "gonadotrophin- releasing hormone (GnRH, gonadorelin) and its agonist analogues".10 The entry carries the qualifier "in males" in its heading.10
Storage and handling
Sources in this part
What is not known
Sources in this part
No controlled trial in people of a single subcutaneous triptorelin dose as an axis restart after anabolic steroid use was identified in PubMed or ClinicalTrials.gov, so the app's use and its 100 to 200 mcg range rest on pharmacology and on stimulation-test and trigger studies in other groups. How many doses, or how closely spaced, would tip stimulation into suppression is not stated by the sources cited here; the label gives the onset of suppression as "usually 2 to 4 weeks" with continuous depot administration.2 The label states that "The effects of age and race on triptorelin pharmacokinetics have not been systematically studied" and that "No studies were conducted to assess the effect of triptorelin on male fertility".2 The app's 90% bioavailability and 24-hour duration have no direct source figure in the material cited here.
Frequently asked questions
What is the half-life of triptorelin?
Müller and colleagues measured a geometric mean elimination half-life of 2.8 hours in healthy men after a 0.5 mg intravenous dose, and the app lists 3 hours.1 The Trelstar label gives approximately 3 hours as the last of three half-lives after an intravenous bolus in healthy men.2 In men with renal or hepatic insufficiency the same study reported 6.6 to 7.7 hours.1
Is triptorelin banned by WADA?
The 2026 WADA Prohibited List names triptorelin among the GnRH agonist analogues under S2.2.1, "Testosterone-stimulating peptides in males".10
What is triptorelin approved for?
Does triptorelin raise or lower testosterone?
How long does triptorelin take to peak?
The Trelstar label gives peak serum concentrations 1 to 3 hours after an intramuscular depot injection in men with prostate cancer, and the app lists about 1 hour for the subcutaneous dose.2 In children with central precocious puberty, the Triptodur label gives a peak 4 hours after a 22.5 mg injection.3
What is the bioavailability of triptorelin?
Is Decapeptyl the same as Trelstar?
What side effects are listed on the triptorelin labels?
The Trelstar label lists hot flushes among the most common adverse reactions at all three strengths, with tumor flare, metabolic changes and cardiovascular events in men among its warnings.2
Has triptorelin been tested as a post-cycle restart?
No controlled trial in people of a single triptorelin dose as a restart after anabolic steroid use was identified in PubMed or ClinicalTrials.gov.
Guides, tools and comparisons
References
- Müller FO, et al. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 1997. PMID 9354307
- Verity Pharmaceuticals. Trelstar (triptorelin pamoate for injectable suspension), for intramuscular use. US prescribing information, DailyMed version 20, 2026. DailyMed label (Trelstar)
- Azurity Pharmaceuticals. Triptodur (triptorelin) extended-release injectable suspension. US prescribing information, DailyMed version 16, 2025. DailyMed label (Triptodur)
- Evans RM, et al. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men. J Clin Endocrinol Metab 1984. PMID 6423661
- Ahn J, et al. Use of the Subcutaneous Triptorelin Stimulation Test for Diagnosis of Central Precocious Puberty. Children (Basel) 2023. PMID 38002921
- Ozkan B, et al. A practical GnRH analogue (triptorelin) stimulation test to distinguish constitutional delay of puberty from hypogonadotropic hypogonadism in prepubertal boys. Turk J Pediatr 2001. PMID 11432487
- Vuong TN, et al. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril 2016. PMID 26523330
- Lainas GT, et al. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome? Hum Reprod 2019. PMID 31384921
- Debiopharm International SA. Study on efficacy, pharmacokinetics, and safety of two subcutaneous injections of triptorelin embonate 6 month formulation in patients with advanced prostate cancer. ClinicalTrials.gov NCT01656161. NCT01656161
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list